The discovery of genotype 16 as the prototype oncogenic human papillomavirus (HPV)
initiated a quarter century of laboratory and epidemiological studies that demonstrated their …

It is easy to argue that vaccine development represents humankind's most important and
successful endeavour, such is the impact that vaccination has had on human morbidity and …

HPV-related diseases represent a major cause of morbidity and mortality, although effective
HPV vaccines are available, potentially allowing for the elimination of these malignancies …

Introduction Human papillomavirus (HPV) infection, which poses significant disease burden,
is decreasing following implementation of vaccination programs. Synthesized evidence on …

The development of human papillomavirus (HPV) vaccines has made substantive progress,
as represented by the approval of five prophylactic vaccines since 2006. Generally, the …

(1) Introduction: A Romanian woman is diagnosed with cervical cancer every two hours; the
country ranks second in Europe in terms of the mortality and incidence rate of this disease …

Background Uptake of human papillomavirus (HPV) vaccine remains low in many countries,
although the bivalent and quadrivalent HPV vaccines given as a three‐dose schedule are …

Men should not be overlooked in research on human papillomavirus (HPV) and its
associated genital diseases. This is because men infected with HPV are not only at higher …

Background Quadrivalent and bivalent vaccines against oncogenic human papillomavirus
(HPV) are used worldwide with different reported overall efficacies against HPV infections …

Background The extent of cross-protection provided by currently licensed bivalent and
quadrivalent HPV vaccines versus direct protection against HPV 31-, 33-, 45-, 52-, and 58 …